<DOC>
	<DOCNO>NCT01524783</DOCNO>
	<brief_summary>The purpose study compare antitumor activity everolimus plus best supportive care versus placebo plus best supportive care patient advance nonfunctional neuroendocrine tumor gastrointestinal lung origin .</brief_summary>
	<brief_title>Everolimus Plus Best Supportive Care v Placebo Plus Best Supportive Care Treatment Patients With Advanced Neuroendocrine Tumors ( GI Lung Origin )</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Pathologically confirm , well differentiate ( G1 G2 ) , advance ( unresectable metastatic ) , neuroendocrine tumor GI lung origin No history active symptom relate carcinoid syndrome In addition treatmentnaive patient , patient previously treat SSA , Interferon ( IFN ) , one prior line chemotherapy , and/or PRRT allow study . Pretreated patient must progress last treatment Radiological document disease progression within 6 month prior randomization Measurable disease WHO performance status ≤1 Adequate bone marrow , liver renal function Patients poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , pancreatic islet cell carcinoma , insulinoma , glucagonoma , gastrinoma , goblet cell carcinoid , large cell neuroendocrine carcinoma small cell carcinoma Patients pancreatic NET NET origins GI Lung Patients history active symptom carcinoid syndrome ( e.g . flushing , diarrhea ) Patients one line prior chemotherapy Prior target therapy Hepatic locoregional therapy within last 6 month Prior therapy mTOR inhibitor ( e.g . sirolimus , temsirolimus , deforolimus ) Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior randomization , serious uncontrolled cardiac arrhythmia active uncontrolled severe infection liver disease cirrhosis , decompensated liver disease , chronic hepatitis ( i.e . quantifiable HBVDNA and/or positive HbsAg , quantifiable HCVRNA ) Chronic treatment corticosteroid immunosuppressive agent Known history HIV seropositivity Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>NET</keyword>
	<keyword>progressive</keyword>
	<keyword>advanced</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>GI lung origin</keyword>
	<keyword>nonfunctional</keyword>
	<keyword>everolimus</keyword>
	<keyword>Advanced NET GI origin</keyword>
	<keyword>Advanced NET lung origin</keyword>
</DOC>